Memantine Mylan

Memantine hydrochloride, the active ingredient in Memantine Mylan, is a non‑competitive NMDA receptor antagonist presented as an oral tablet formulation for oral administration. It is indicated for the symptomatic treatment of moderate to severe Alzheimer’s disease in adult patients, helping to improve cognition and daily functioning.

GNH USA supplies Memantine Mylan as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, with established quality‑assurance processes and regulatory compliance across EU and other markets, and ensuring product integrity from manufacturing to delivery.

Memantine Mylan is an NMDA receptor antagonist used in the management of neurodegenerative dementia conditions.

Alzheimer’s disease (moderate to severe): improves cognition and functional abilities in patients with moderate to severe disease. Dementia associated with Parkinson’s disease (moderate to severe): helps maintain cognitive performance in this patient group. Other forms of moderate to severe dementia: provides symptomatic relief of cognitive symptoms.

Common Side Effects: - Dizziness - Headache - Constipation - Nausea - Fatigue - Confusion

Serious or Rare Side Effects: - Seizures - Severe allergic reactions (e.g., rash, angioedema) - Hallucinations or psychotic symptoms - Cardiac arrhythmias - Elevated liver enzymes

Memantine Mylan should be used with caution in the following situations: - Renal impairment: dose adjustment may be required. - History of seizures: monitor for increased seizure activity. - Cardiovascular disease: use cautiously and monitor blood pressure. - Psychiatric disorders: observe for worsening of mood or psychosis. - Concomitant medications: review potential drug interactions before initiating therapy. - Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Memantine Mylan may interact with several medicines that affect the central nervous system or renal clearance.

Major Interactions (Avoid): - Amantadine: additive CNS effects may increase dizziness or confusion. - Ketamine: combined NMDA antagonism can lead to profound neuro‑psychiatric effects.

Moderate Interactions (Monitor Closely): - Anticholinergic agents: may exacerbate cognitive impairment. - Loop diuretics: increased risk of dehydration and hypotension. - Antihypertensive drugs: potential for additive blood‑pressure lowering.